Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
Jazz Pharmaceuticals Plc
sales of 1.93 billion Euros [US$2.34 billion]
of which 76%
H. Lundbeck A/S
(17.04 billion Danish Kroner [US$2.77 billion]
of which 100%
was Pharmaceuticals), and
Stada Arzneimittel AG
based in GERMANY
(2.61 billion Euros [US$3.16 billion]
of which 59%
During the year ended December of 2019, sales at
Lonza Group AG were 5.92 billion Swiss Francs (US$6.61 billion).
increase of 6.8%
versus 2018, when the company's sales were 5.54 billion Swiss Francs.
This was the fifth consecutive year of sales increases at Lonza Group AG
(and since 2014, sales have increased a total of 63%).
Sales of Eliminations saw an increase
that was more than double the company's growth rate: sales were up
57.9% in 2019, from
38.00 million Swiss Francs to 60.00 million Swiss Francs.
Lonza Group AG also saw significant increases in sales in
Pharma&biotech (up 33.9% to 4.17 billion Swiss Francs)
Not all segments of Lonza Group AG experienced an increase in sales in 2019:
sales of Specialty Ingredients fell 29.2% to 1.69 billion Swiss Francs.